BioStem Technologies, Inc. filed a Form D with the Securities and Exchange Commission on 2026-06-03.
BioStem Technologies, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 3, 2026. BioStem Technologies, Inc. trades on Nasdaq as BSEM; it was formerly Biostem Technologies. The filing reports $2.50M sold. Its industry group is Biotechnology. It names Jason Matuszewski (Executive Officer, Director), Brandon Poe (Executive Officer), Andrew Van Vurst (Executive Officer, Director) (SEC Form D, June 3, 2026).
In its own words: “BioStem Technologies® produces innovative perinatal tissue-based allografts, including VENDAJE®, VENDAJE AC® and VENDAJE® optic.” (biostemtechnologies.com, checked November 1, 2026)
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like BioStem Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-06-03 · the record
Pitching, partnering or investing alongside them? See who really runs and owns BioStem Technologies, Inc.
Free to see. No signup.
More on the people and the money behind BioStem Technologies, Inc., from the filings we hold.
Biotechnology raises by companies based in Florida, filed in June 2026, largest first.
Get an email when BioStem Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when BioStem Technologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch BioStem Technologies, Inc. →Get the full cited report on BioStem Technologies, Inc.
What the filing shows about BioStem Technologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioStem Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives BioStem Technologies, Inc.'s address as 2836 Center Port Circle, Pompano Beach, FL 33064.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for BioStem Technologies, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on BioStem Technologies, Inc. See pricing
BioStem Technologies, Inc. is a registered filer with the SEC (CIK 1658678) and has filed since 2023-04-04. 4 filings are on record, the latest on 2026-10-09.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
BioStem Technologies, Inc.'s Form D of 2026-06-03 names Jason Matuszewski, Brandon Poe, Andrew Van Vurst and 6 more as its officers, directors or promoters.
Its new offerings report $5.72M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $2.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
BioStem Technologies® produces innovative perinatal tissue-based allografts, including VENDAJE®, VENDAJE AC® and VENDAJE® optic.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Jason Matuszewski is named as Executive Officer and Director on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Brandon Poe is named as Executive Officer on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Andrew Van Vurst is named as Executive Officer and Director on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Barry Hassett is named as Executive Officer on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Katherine Gorrell is named as Executive Officer on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Kenneth Warrington is named as Director on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Thomas Dugan is named as Director on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Patrick Daly is named as Director on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
Jodi Ungrodt is named as Director on the Form D that BioStem Technologies, Inc. filed with the SEC on 3 June 2026, one of 9 people that filing names.
9 people named on the filing — 5 holding an executive role and 4 as directors only.
Named as of the 2026-06-03 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about BioStem Technologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioStem Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioStem Technologies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist BioStem Technologies, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind BioStem Technologies, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (biostemtechnologies.com).
Each opens in a new tab, filled in for BioStem Technologies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Miami
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/biostem-technologies-inc-form-d-26000001